Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic

Nicole C. Schmidt, José Roman-Pouriet, Aracelis D. Fernandez, Consuelo M. Beck-Sagué, José Leonardo-Guerrero, Stephen W. Nicholas

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: To investigate whether costs of multidose antiretroviral regimens (MD-ARVs), including highly active antiretroviral therapy (HAART), for prevention of mother-to-child transmission (PMTCT) of HIV might be offset by savings gained from treating fewer perinatally acquired infections. Methods: Rates of MTCT reported in the Dominican Republic among mother-infant pairs treated with single-dose nevirapine (SD-NVP; n = 39) and MD-ARVs (n = 91) for PMTCT were compared. Annual births to women infected with HIV were estimated from seroprevalence studies. Antiretroviral costs for both PMTCT and for HAART during the first 2 years of life (in cases of perinatal infection) were based on 2008 low-income country price estimates. Results: Rates of MTCT were 3.3% and 15.4% for the MD-ARV and SD-NVP groups, respectively (P = 0.02). Assuming that 5775 of 231 000 annual births (2.5%) were to HIV-positive women, it was estimated that 191 perinatally acquired infections would occur using MD-ARVs and 889 using SD-NVP. High costs of maternal MD-ARVs (HAART, US$914,760 versus SD-NVP, $1155) would be offset by lower 2-year HAART costs ($250,344 versus $1,168,272 for infants in the SD-NVP group) for the lower number of children with prenatally acquired infection (191 versus 889) associated with the use of MD-ARVs for PMTCT (net national saving $3168). Conclusion: Despite the high costs, use of MD-ARVs, such as HAART, for PMTCT offer societal savings because fewer perinatally acquired infections are anticipated to require treatment.

Original languageEnglish (US)
Pages (from-to)219-222
Number of pages4
JournalInternational Journal of Gynecology and Obstetrics
Volume116
Issue number3
DOIs
StatePublished - Mar 2012
Externally publishedYes

Fingerprint

Dominican Republic
Cost-Benefit Analysis
Highly Active Antiretroviral Therapy
Mothers
HIV
Costs and Cost Analysis
Infection
Therapeutics
Parturition
Nevirapine
Seroepidemiologic Studies

Keywords

  • Antiretroviral regimens
  • Cost-benefit analysis
  • Highly active antiretroviral therapy
  • HIV
  • Mother-to-child transmission
  • Prevention

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic. / Schmidt, Nicole C.; Roman-Pouriet, José; Fernandez, Aracelis D.; Beck-Sagué, Consuelo M.; Leonardo-Guerrero, José; Nicholas, Stephen W.

In: International Journal of Gynecology and Obstetrics, Vol. 116, No. 3, 03.2012, p. 219-222.

Research output: Contribution to journalArticle

Schmidt, Nicole C. ; Roman-Pouriet, José ; Fernandez, Aracelis D. ; Beck-Sagué, Consuelo M. ; Leonardo-Guerrero, José ; Nicholas, Stephen W. / Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic. In: International Journal of Gynecology and Obstetrics. 2012 ; Vol. 116, No. 3. pp. 219-222.
@article{6e2d0210b8004e0782f8efccf3add8ab,
title = "Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic",
abstract = "Objective: To investigate whether costs of multidose antiretroviral regimens (MD-ARVs), including highly active antiretroviral therapy (HAART), for prevention of mother-to-child transmission (PMTCT) of HIV might be offset by savings gained from treating fewer perinatally acquired infections. Methods: Rates of MTCT reported in the Dominican Republic among mother-infant pairs treated with single-dose nevirapine (SD-NVP; n = 39) and MD-ARVs (n = 91) for PMTCT were compared. Annual births to women infected with HIV were estimated from seroprevalence studies. Antiretroviral costs for both PMTCT and for HAART during the first 2 years of life (in cases of perinatal infection) were based on 2008 low-income country price estimates. Results: Rates of MTCT were 3.3{\%} and 15.4{\%} for the MD-ARV and SD-NVP groups, respectively (P = 0.02). Assuming that 5775 of 231 000 annual births (2.5{\%}) were to HIV-positive women, it was estimated that 191 perinatally acquired infections would occur using MD-ARVs and 889 using SD-NVP. High costs of maternal MD-ARVs (HAART, US$914,760 versus SD-NVP, $1155) would be offset by lower 2-year HAART costs ($250,344 versus $1,168,272 for infants in the SD-NVP group) for the lower number of children with prenatally acquired infection (191 versus 889) associated with the use of MD-ARVs for PMTCT (net national saving $3168). Conclusion: Despite the high costs, use of MD-ARVs, such as HAART, for PMTCT offer societal savings because fewer perinatally acquired infections are anticipated to require treatment.",
keywords = "Antiretroviral regimens, Cost-benefit analysis, Highly active antiretroviral therapy, HIV, Mother-to-child transmission, Prevention",
author = "Schmidt, {Nicole C.} and Jos{\'e} Roman-Pouriet and Fernandez, {Aracelis D.} and Beck-Sagu{\'e}, {Consuelo M.} and Jos{\'e} Leonardo-Guerrero and Nicholas, {Stephen W.}",
year = "2012",
month = "3",
doi = "10.1016/j.ijgo.2011.10.028",
language = "English (US)",
volume = "116",
pages = "219--222",
journal = "International Journal of Gynecology and Obstetrics",
issn = "0020-7292",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic

AU - Schmidt, Nicole C.

AU - Roman-Pouriet, José

AU - Fernandez, Aracelis D.

AU - Beck-Sagué, Consuelo M.

AU - Leonardo-Guerrero, José

AU - Nicholas, Stephen W.

PY - 2012/3

Y1 - 2012/3

N2 - Objective: To investigate whether costs of multidose antiretroviral regimens (MD-ARVs), including highly active antiretroviral therapy (HAART), for prevention of mother-to-child transmission (PMTCT) of HIV might be offset by savings gained from treating fewer perinatally acquired infections. Methods: Rates of MTCT reported in the Dominican Republic among mother-infant pairs treated with single-dose nevirapine (SD-NVP; n = 39) and MD-ARVs (n = 91) for PMTCT were compared. Annual births to women infected with HIV were estimated from seroprevalence studies. Antiretroviral costs for both PMTCT and for HAART during the first 2 years of life (in cases of perinatal infection) were based on 2008 low-income country price estimates. Results: Rates of MTCT were 3.3% and 15.4% for the MD-ARV and SD-NVP groups, respectively (P = 0.02). Assuming that 5775 of 231 000 annual births (2.5%) were to HIV-positive women, it was estimated that 191 perinatally acquired infections would occur using MD-ARVs and 889 using SD-NVP. High costs of maternal MD-ARVs (HAART, US$914,760 versus SD-NVP, $1155) would be offset by lower 2-year HAART costs ($250,344 versus $1,168,272 for infants in the SD-NVP group) for the lower number of children with prenatally acquired infection (191 versus 889) associated with the use of MD-ARVs for PMTCT (net national saving $3168). Conclusion: Despite the high costs, use of MD-ARVs, such as HAART, for PMTCT offer societal savings because fewer perinatally acquired infections are anticipated to require treatment.

AB - Objective: To investigate whether costs of multidose antiretroviral regimens (MD-ARVs), including highly active antiretroviral therapy (HAART), for prevention of mother-to-child transmission (PMTCT) of HIV might be offset by savings gained from treating fewer perinatally acquired infections. Methods: Rates of MTCT reported in the Dominican Republic among mother-infant pairs treated with single-dose nevirapine (SD-NVP; n = 39) and MD-ARVs (n = 91) for PMTCT were compared. Annual births to women infected with HIV were estimated from seroprevalence studies. Antiretroviral costs for both PMTCT and for HAART during the first 2 years of life (in cases of perinatal infection) were based on 2008 low-income country price estimates. Results: Rates of MTCT were 3.3% and 15.4% for the MD-ARV and SD-NVP groups, respectively (P = 0.02). Assuming that 5775 of 231 000 annual births (2.5%) were to HIV-positive women, it was estimated that 191 perinatally acquired infections would occur using MD-ARVs and 889 using SD-NVP. High costs of maternal MD-ARVs (HAART, US$914,760 versus SD-NVP, $1155) would be offset by lower 2-year HAART costs ($250,344 versus $1,168,272 for infants in the SD-NVP group) for the lower number of children with prenatally acquired infection (191 versus 889) associated with the use of MD-ARVs for PMTCT (net national saving $3168). Conclusion: Despite the high costs, use of MD-ARVs, such as HAART, for PMTCT offer societal savings because fewer perinatally acquired infections are anticipated to require treatment.

KW - Antiretroviral regimens

KW - Cost-benefit analysis

KW - Highly active antiretroviral therapy

KW - HIV

KW - Mother-to-child transmission

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=84856623838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856623838&partnerID=8YFLogxK

U2 - 10.1016/j.ijgo.2011.10.028

DO - 10.1016/j.ijgo.2011.10.028

M3 - Article

VL - 116

SP - 219

EP - 222

JO - International Journal of Gynecology and Obstetrics

JF - International Journal of Gynecology and Obstetrics

SN - 0020-7292

IS - 3

ER -